SCHEMBL186150

SCHEMBL186150

CC(C)(C[Si](C)(C)C(C)(C)C)[Si](c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18523534 0.76 RIPK1 (0.32)
SCHEMBL17559963 0.74
SCHEMBL8933622 0.71 TSHR (0.35) LMNA
SCHEMBL17529803 0.69 GAA (0.33)
SCHEMBL9242665 0.67
SCHEMBL6226452 0.67 TAAR1 (0.38) KMT2A
SCHEMBL18397 0.67 MAPK1 (0.36) MEN1KMT2ALMNACYP2D6
SCHEMBL28898247 0.66
Hydrochloric Acid SCHEMBL22288246 0.65 MAPK1 (0.35) MEN1KMT2ALMNACYP2D6
SCHEMBL1618736 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232177-A Chemical synthesis method of shigella dysenteriae type 10O-antigen oligosaccharide 江南大学 2022-10-25 CN claimed
US-20170349520-A1 SINGLY PROTECTED 2,2' -DIHYDROXYBIARYLS EVONIK DEGUSSA GMBH (DE) 2017-12-07 US claimed
US-8969546-B2 Compounds useful in imaging and therapy THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2015-03-03 US claimed
US-20130211066-A1 COMPOUNDS USEFUL IN IMAGING AND THERAPY ALBERTA HEALTH SERVICES (CA) 2013-08-15 US claimed
CN-115568282-A Use of anti-aging glycopeptides to treat dry eye, retinal degenerative diseases, or ocular inflammation 普罗托基尼蒂克有限公司 2023-01-03 CN disclosed
CN-114787139-A Processes and intermediates for preparing MCL1 inhibitors 吉利德科学公司 2022-07-22 CN disclosed
US-20170349520-A1 SINGLY PROTECTED 2,2' -DIHYDROXYBIARYLS EVONIK DEGUSSA GMBH (DE) 2017-12-07 US disclosed
EP-3189176-A1 ONE-SIDED PROTECTED 2,2 -DIHYDROXY BIARYLS AND ELECTROCHEMICAL METHOD FOR THE PRODUCTION THEREOF Evonik Degussa GmbH (DE) 2017-07-12 EP disclosed
WO-2016034326-A1 ONE-SIDED PROTECTED 2,2 -DIHYDROXY BIARYLS AND ELECTROCHEMICAL METHOD FOR THE PRODUCTION THEREOF EVONIK DEGUSSA GMBH (DE) 2016-03-10 WO disclosed
US-20160002275-A1 PROCESS FOR PREPARATION AND PURIFICATION OF CANAGLIFLOZIN CADILA HEALTHCARE LIMITED (IN) 2016-01-07 US disclosed
US-8969546-B2 Compounds useful in imaging and therapy THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2015-03-03 US disclosed
US-20130211066-A1 COMPOUNDS USEFUL IN IMAGING AND THERAPY ALBERTA HEALTH SERVICES (CA) 2013-08-15 US disclosed
WO-2011160216-A2 COMPOUNDS USEFUL IN IMAGING AND THERAPY THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2011-12-29 WO disclosed
US-20090294369-A1 Selective Fixing Agents for Halogenated Aromatic Compounds Contained in Media and Method for Selective Fixing OSAKA UNIVERSITY (JP) 2009-12-03 US disclosed
EP-2067801-A1 Synthesis of Hybrid Block Copolymers Intezyne Technologies Incorporated (US) 2009-06-10 EP disclosed
EP-2017317-A1 SELECTIVE STICKING AGENTS FOR HALOGENATED AROMATIC COMPOUNDS CONTAINED IN MEDIA AND METHOD FOR SELECTIVE STICKING Neos Co., Ltd. (JP) 2009-01-21 EP disclosed
EP-2001885-A2 OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES Abbott Laboratories (US) 2008-12-17 EP disclosed
WO-2007100990-A2 OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2007-09-07 WO disclosed
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US disclosed
US-6162808-A Compounds ASTRAZENECA U.K. LIMITED (GB) 2000-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors ALOX15, ALOX5, ALOX12 MEN1 4793/4885KMT2A 2042/4885LMNA 1070/4885
US-20130211066-A1 COMPOUNDS USEFUL IN IMAGING AND THERAPY PAICS, MPI, ALDOA MEN1 1006/4885KMT2A 1008/4885LMNA 2442/4885
US-20160002275-A1 PROCESS FOR PREPARATION AND PURIFICATION OF CANAGLIFLOZIN SLC5A2, SLC5A1, SLC2A4 MEN1 3555/4885KMT2A 3878/4885LMNA 3826/4885
US-20170349520-A1 SINGLY PROTECTED 2,2' -DIHYDROXYBIARYLS DBH, COMT, DRD2 MEN1 1920/4885KMT2A 2303/4885LMNA 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.